Gal Antman*, Gali Abrahami, Ori Berliner, Rita Erlich, Ehud Reich, Michal Kramer and Yael Sharon
Purpose: To report a novel ocular inflammatory adverse event to brentuximab vedotin, an anti-CD-30 agent, in a young patient with Hodgkin’s lymphoma. Methods: Case report Results: A 19-year-old female presented with bilateral profound decreased vision due to anterior and intermediate uveitis while being treated with brentuximab, for recurrence of Hodgkin’s lymphoma. Treatment with brentuximab was halted and the patient was treated with intravenous steroids and improved dramatically. Infectious and masquerade etiologies were ruled out. Conclusion: This is the first report of an ocular inflammatory adverse event to brentuximab as a monotherapy. Despite its rarity, ocular responses to biologic agents should be added to the differential diagnosis of intraocular inflammation and treating physicians should be aware of this potential side effect. It is suggested that the American Society of Clinical Oncology Guidelines for the management of immune-related adverse events in patients treated with immune checkpoint inhibitor agents be employed in these cases as well.
English 
Spanish 
Chinese 
German 
French 
Japanese 
Portuguese 
Hindi